Hepatocyte growth factor - Kringle Pharma

Drug Profile

Hepatocyte growth factor - Kringle Pharma

Alternative Names: KP-100IT

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kringle Pharma
  • Developer Keio University School of Medicine; Kringle Pharma
  • Class Antifibrotics; Growth factors; Neuropsychotherapeutics
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell death inhibitors; Proto oncogene protein c met modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Scars; Spinal cord injuries
  • Phase I Acute kidney injury
  • No development reported Renal failure

Most Recent Events

  • 13 Nov 2017 Kringle Pharma completes a phase II trial in Amyotrophic lateral sclerosis in Japan (Intrathecal) (UMIN000022050)
  • 29 Dec 2016 Phase-I clinical trials in Acute kidney injury in USA before December 2016 (Kringle Pharma website, December 2016)
  • 29 Dec 2016 Phase-I/II clinical trials in Scars in Japan before December 2016 (Kringle Pharma pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top